Profile data is unavailable for this security.
About the company
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.
- Revenue in CNY (TTM)30.98bn
- Net income in CNY7.47bn
- Incorporated1997
- Employees20.24k
- LocationJiangsu Hengrui Pharmaceuticals Co LtdNo.7 Kunlunshan RoadLianyungang Eco & Tech Development ZoneLIANYUNGANG 222000ChinaCHN
- Phone+86 2 161053323
- Fax+86 2 161063801
- Websitehttps://www.hengrui.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 25.66bn | 2.17bn | 288.07bn | 2.50k | 140.03 | 52.74 | 112.88 | 11.23 | 2.25 | 2.25 | 27.82 | 5.96 | 0.8068 | 8.46 | 7.20 | 1,485,575.00 | 6.82 | -12.28 | 9.57 | -16.14 | 81.64 | 83.20 | 8.45 | -24.70 | 2.71 | 3.50 | 0.7737 | -- | 65.19 | 49.77 | 212.79 | -- | -3.56 | -- |
| Sun Pharmaceutical Industries Ltd | 43.34bn | 8.01bn | 310.73bn | 43.00k | 38.85 | -- | 30.38 | 7.17 | 43.70 | 45.45 | 236.59 | -- | -- | -- | -- | 13,211,420.00 | -- | 9.09 | -- | 12.38 | 79.97 | 73.38 | 18.62 | 16.07 | -- | -- | -- | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Haleon PLC | -942.99bn | -942.99bn | 343.69bn | 24.00k | -- | 2.31 | -- | -- | -- | -- | -- | 1.77 | -- | -- | -- | -- | -- | 3.67 | -- | 4.23 | -- | 62.28 | -- | 11.97 | 0.6327 | -- | 0.3464 | 218.58 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| CSL Ltd | 107.29bn | 20.70bn | 355.73bn | 32.07k | 17.22 | 2.66 | 12.42 | 3.32 | 8.71 | 8.71 | 45.14 | 56.34 | 0.4019 | 1.20 | 5.16 | 684,542.30 | 8.10 | 8.58 | 9.87 | 10.61 | 51.93 | 52.91 | 20.16 | 19.71 | 1.12 | 10.01 | 0.3494 | 47.42 | 5.12 | 11.20 | 13.63 | 7.38 | -6.11 | 7.95 |
| Zoetis Inc | 65.40bn | 18.47bn | 369.35bn | 14.50k | 21.03 | -- | 16.90 | 5.65 | 6.02 | 6.02 | 21.33 | -- | -- | -- | -- | 652,896.60 | -- | 16.21 | -- | 19.61 | 71.87 | 70.68 | 28.23 | 27.03 | -- | 20.95 | -- | 30.59 | 2.28 | 7.24 | 7.52 | 10.29 | 6.51 | 20.11 |
| Bayer AG | 376.08bn | -1.62bn | 370.43bn | 88.50k | -- | 1.53 | 13.28 | 0.985 | -0.2015 | -0.2015 | 46.69 | 30.11 | 0.4344 | 1.58 | 4.52 | 494,165.80 | -0.1639 | -2.66 | -0.2205 | -3.61 | 56.35 | 57.98 | -0.3772 | -6.88 | 0.7096 | 2.33 | 0.5717 | -- | -2.16 | 1.37 | 13.23 | -- | 0.9479 | -47.66 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 30.98bn | 7.47bn | 371.45bn | 20.24k | 49.69 | 6.50 | -- | 11.99 | 1.17 | 1.17 | 4.84 | 8.97 | 0.5312 | 1.71 | 5.75 | 1,530,951.00 | 12.82 | 12.67 | 14.40 | 14.00 | 85.49 | 85.64 | 24.14 | 20.06 | 6.20 | -- | 0.0014 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| Takeda Pharmaceutical Co Ltd | 201.99bn | 5.11bn | 404.09bn | 47.46k | 77.69 | 1.16 | 10.38 | 2.00 | 72.26 | 72.26 | 2,834.46 | 4,838.54 | 0.2926 | 1.17 | 6.17 | 94,080,250.00 | 0.7418 | 1.71 | 0.8772 | 2.04 | 65.33 | 67.66 | 2.54 | 5.99 | 0.6548 | 3.49 | 0.3884 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| UCB SA | 56.15bn | 10.92bn | 445.76bn | 9.38k | 40.74 | 5.48 | 28.43 | 7.94 | 6.86 | 6.86 | 35.27 | 50.96 | 0.4174 | 1.46 | 4.26 | 730,219.70 | 8.12 | 4.98 | 10.21 | 6.20 | 73.38 | 71.71 | 19.45 | 13.00 | 1.01 | 11.23 | 0.2291 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| Merck KGaA | 174.41bn | 24.23bn | 455.60bn | 62.35k | 18.81 | 1.92 | 11.41 | 2.61 | 6.79 | 6.79 | 48.92 | 66.55 | 0.4209 | 1.97 | 5.04 | 340,025.90 | 5.85 | 6.04 | 7.23 | 7.70 | 58.69 | 61.15 | 13.91 | 13.80 | 0.9686 | 18.28 | 0.2943 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
Data as of Feb 13 2026. Currency figures normalised to Jiangsu Hengrui Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
12.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 180.14m | 2.83% |
| China Asset Management Co., Ltd.as of 30 Nov 2025 | 153.98m | 2.42% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 91.05m | 1.43% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 83.08m | 1.31% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 68.52m | 1.08% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 54.31m | 0.85% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 54.03m | 0.85% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 30.15m | 0.47% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2025 | 26.97m | 0.42% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 25.83m | 0.41% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
